Cargando…

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY

Detalles Bibliográficos
Autores principales:	Offidani, M., Zizzo, C., Rupoli, S., Federici, I., Bossi, A., Morè, S., Manieri, V. M., Petrucci, M. T., Caravita di Toritto, T., Brunori, M., Gozzetti, A., Tordi, A., Fazio, F., Lisi, C., Morsia, E., Corvatta, L., Olivieri, A., Duro, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431414/ http://dx.doi.org/10.1097/01.HS9.0000850928.87639.6b

Ejemplares similares

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

P912: ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION
por: More’, Sonia, et al.
Publicado: (2023)

P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE
por: Morè, S., et al.
Publicado: (2023)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Novel Experimental Drugs for Treatment of Multiple Myeloma
por: Offidani, Massimo, et al.
Publicado: (2021)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

Identifying the link between multiple myeloma and neurofibromatosis type I
por: Rago, Angela, et al.
Publicado: (2020)

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications
por: Morsia, Erika, et al.
Publicado: (2022)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
por: Morsia, E., et al.
Publicado: (2022)

Hemochromatosis Mimicked Gaucher Disease: Role of Hyperferritinemia in Evaluation of a Clinical Case
por: Zizzo, Carmela, et al.
Publicado: (2022)

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
por: Morsia, E, et al.
Publicado: (2021)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary “Real Life” Experience
por: Rupoli, Serena, et al.
Publicado: (2021)

2024 MERIT Guidelines
por: Stappers, Sara
Publicado: (2023)

We are Ready for 2024!
Publicado: (2023)

PB2189: UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.
por: Morsia, Erika, et al.
Publicado: (2023)

P1109: EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.
por: Morsia, Erika, et al.
Publicado: (2023)

P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
por: Giuffrida, G., et al.
Publicado: (2022)

Medium-Term Plan for the period 2024-2028 and Draft Budget of the Organization for the seventieth financial year 2024
Publicado: (2023)

LHCb Computing Resources: 2024 requests
por: Bozzi, Concezio
Publicado: (2023)

Immunotactoid glomerulopathy and chronic lymphocytic leukemia: The need for a multidisciplinary approach
por: Rago, Angela, et al.
Publicado: (2022)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

The Plant Cell is accepting applications for assistant features editors for 2024
por: Eckardt, Nancy A, et al.
Publicado: (2023)

JARDIN DES PARTICULES - Enrollment 2023/2024
por: Staff Association
Publicado: (2023)

Timetable for Council Sessions and committee meetings in 2024
Publicado: (2022)

Preliminary information on the Cost-Variation Index for 2024
Publicado: (2023)

El Proyecto de Nación 2018 - 2024
por: Editorial, Comité
Publicado: (2019)

LHCb Computing Resources: preliminary 2024 requests
por: Bozzi, Concezio
Publicado: (2022)

See you at ICAM in Vancouver, April 2024!
por: D’Eon, Marcel F
Publicado: (2023)

PReS-FINAL-2024: Responsiveness of the juvenile arthritis foot disability index
por: Esbjörnsson, AC, et al.
Publicado: (2013)

Influence of Solid Solutions on the Al2024 High-Temperature Deformation Behavior
por: Ruano, Oscar A., et al.
Publicado: (2023)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

Propuestas estratégicas para el desarrollo 2019-2024 /
Publicado: (2018)

2024 Scale of Contributions by the Member and Associate Member States
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5q84holjkfir5eo18lklek3jad